1 to prevent fetal infection and the other for treatment of infected fetuses [2] . Randomized trials for both uses would be optimal; however, for many reasons, no randomized trials are ongoing or being contemplated for treatment of infected fetuses. Therefore my editorial commentary was clearly directed toward treatment options [1, 3] . For prevention, 1 randomized trial, which used the identical Nigro prevention protocol, was not negative but rather showed an efficacy rate lower than but consistent with that observed by Nigro et al for the prevention of fetal infection. The good news is that for the prevention of fetal infection after primary maternal infection during pregnancy there are 2 important clinical trials in progress. One trial in the United States is sponsored by the Eunice Kennedy Shriver National Institutes of Child Health and Human Development Maternal Fetal Medicine Units Network, and enrollment just commenced. It is a double-blinded, randomized, placebocontrolled trial that will enroll 800 women at 14 centers across the United States and will have adequate power to detect a one-third reduction in the rate of congenital infection with the use of CMV hyperimmune globulin. The other trial is in Europe, is sponsored by Biotest, and is a randomized, open label trial. Both trials serologically screen pregnant women for antibodies to CMV, and those who seroconvert in the first 36 weeks of gestation are randomized to receive either monthly hyperimmune globulin or nothing. Successful enrollment and completion of both trials is essential for determining the true efficacy of prophylactic hyperimmune globulin during pregnancy. 
